ClinicalTrials.gg
CompletedNCT02184611Updated Jun 29, 2020Results posted

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

A Phase 3 interventional study of Umeclidinium bromide and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 26 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-06-29.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
74th of 236
308 · median 101
Started
2016
with 10 others
Phase 3
65 of 276
5 open now
Registered
193rd of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 74th largest by enrollment of the 236 interventional ones that give a count, is one of 11 that started in 2016, is one of 65 in phase 3, and was the 193rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg administered once-daily (OD) for 24 weeks via a NDPI compared with placebo in Asian subjects with COPD. Over approximate 27 weeks of entire study duration, 10 study clinic visits will be conducted on an outpatient basis. Pre-screening visit will be conducted for the informed consent form, review demography, COPD history and COPD concomitant medications. Subjects meeting the eligibility criteria at screening will complete a 7 to 14 day Run-in period and will be provided with albuterol/salbutamol as rescue medication on an "as-needed" basis. Further, subjects will be randomized to the UMEC 62.5 mcg or matching placebo in a 1:2 ratio for 24 week treatment period. A follow up for adverse event assessment will be scheduled approximately 7 days after the treatment period or the Early Withdrawal Visit.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • lung function
  • Umeclidinium
  • GSK573719
  • anticholinergic
  • novel dry powder inhaler
  • long-acting muscarinic receptor antagonist
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: outpatient, Asian ancestry.
  • : A signed and dated written informed consent prior to study participation.
  • Age: 40 years of age or older at Screening (Visit 1).
  • Gender: Male or female subjects are eligible to participate in the study. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, >45 years, in the absence of hormone replacement therapy. However, in questionable cases, post-menopause status may be confirmed by analysis of a blood sample with follicle-stimulating hormone (FSH) >40 million international units per milliliter (MIU/ml) and estradiol \<40 picogram (pg) /ml (\<140 picomole per liter (pmol/L) as confirmatory. OR Child bearing potential, provided the subject has a negative pregnancy test at screening, and agrees to one of the following acceptable methods used consistently and correctly (i.e. in accordance with the approved product label, and the instructions of the physician for the duration of the study - Screening to Follow-Up contact): Abstinence\ Oral contraceptive either combined or progestogen alone\ Injectable progestogen\ Implants of levonorgestrel\ Estrogenic vaginal ring\ Percutaneous contraceptive patches\ Intrauterine device (IUD) or intrauterine system (IUS)\ Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and this male is the sole partner for that subject\ Double barrier method condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
  • History: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society as follows: COPD is a preventable and treatable disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
  • Tobacco Use and Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >= 10 pack-years [Number of pack years = (number of cigarettes per day /20) x number of years smoked (e.g. 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years both equal 10 pack years)]. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history. COPD patients who only use a pipe and/or cigar are not eligible.
  • Severity of Disease: A pre and post-salbutamol/albuterol /FVC ratio of \<0.70 and a pre and post-salbutamol/albuterol FEV1 of \<=70% of predicted normal values calculated using National Health and Nutrition Examination Survey III reference equations at Visit 1.
  • Dyspnea: A score of >=2 on the Modified Medical Research Council Dyspnoea Scale (mMRC) at Screening (Visit 1)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: A current diagnosis of asthma.
  • Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis) and lung cancer are absolute exclusionary conditions. A subject, who in the opinion of the investigator has any other significant respiratory conditions in addition to should be excluded. Examples may include bronchiectasis, pulmonary hypertension, sarcoidosis or interstitial lung disease.
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \<5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Chest X-Ray: A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Visit 1 if a chest X-ray or CT scan is not available within 6 months prior to Visit 1.
  • : A history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.
  • Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
  • 12-Lead (ECG): An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, including the presence of a paced rhythm on a 12-lead ECG which causes the underlying rhythm and ECG to be obscured. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. Specific ECG findings that precluded subject eligibility are as listed. An ECG finding that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: Sinus tachycardia ≥120 bpm*Note: sinus tachycardia ≥120bpm should be confirmed by two additional readings at least 5 minutes apart. Sinus bradycardia \<45bpm*Note: Sinus bradycardia \<45bpm should be confirmed by two additional readings at least 5 minutes apart.Multifocal atrial tachycardia.Supraventricular tachycardia (>100bpm).Atrial fibrillation with rapid ventricular response (rate >120bpm). Atrial flutter with rapid ventricular response (rate >120bpm). Ventricular tachycardias (non sustained, sustained, polymorphic, or monomorphic). Ventricular flutter. Ventricular fibrillation. Torsades de Pointes. Evidence of Mobitz type II second degree or third degree atrioventricular (AV) block. AV dissociation. Trifascicular Block. For subjects with QRS duration \<120 ms: (F) ≥450msec or an ECG that is unsuitable for QT measurements (e.g., poor defined termination of the T wave). For subjects with QRS duration>120: QTc(F) ≥480msec or an ECG that is unsuitable for QT measurements (e.g., poor defined termination of the T wave). Myocardial infarction (acute or recent) * Note: Evidence of an old (resolved) myocardial infarction is not exclusionary. The study investigator will determine the medical significance of any ECG abnormalities not listed above.
  • Screening Labs: Significantly abnormal findings from clinical chemistry and haematology tests at Visit 1.
  • Medications Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
  • Medications Prior to Screening: Use of the following medications according to the following defined time intervals prior to Visit 1 is presented as Medication with Time Interval Prior to Visit 1: Depot (12 weeks); Systemic, oral, parenteral (intra-articular) corticosteroids (4 weeks); Antibiotics (for lower respiratory tract infection) (4 weeks); inhaled corticosteroid/ long-acting beta agonist (ICS/LABA) combination products if ICS/LABA therapy is discontinued completely (30 days); Use of ICS at a dose >1000mcg/day of fluticasone propionate or equivalent (30 days); Initiation or discontinuation of ICS use (30 days); Phosphodiesterase 4 (PDE4) inhibitors (roflumilast) (14 days); Long-acting anticholinergics (e.g.,tiotropium and aclidinium, glycopyronium) (7 days); Theophyllines (12 hours stable dose of theophylline alone is allowed during the study but must be withheld 12 hours prior to each study visit); Oral leukotriene inhibitors (zafirlukast, montelukast, zileuton) (48 hours); Oral beta2-agonists (Long- acting 48 hours, Short -acting 12 hours); Olodaterol and Indacaterol (inhaled long-acting beta2-agonist) (14 days); Salmeterol, formoterol, (inhaled long-acting beta2-agonist) (48 hours); LABA/ ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy (48 hours for LABA component); Inhaled sodium cromoglycate or nedocromil sodium (24 hours); Inhaled short acting beta2-agonists (4 hours); Inhaled short-acting anticholinergics (e.g. ipratropium bromide) (4 hours, stable dose of ipratropium alone is allowed during the study, provided that the subject is on a stable dose regimen from Screening [Visit 1 and remains so throughout the study] but must be withheld 4 hours prior to each study visit); Inhaled short-acting anticholinergic/short-acting beta2-agonist combination products (4 hours); Any other drug (30 days or 5 half lives, whichever is longer). Note: Further details related to allowable dosage of above listed medications will be explained by the Investigator)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    Umeclidinium bromide

    Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks

    Drug: Umeclidinium bromide

  • Placebo comparator
    Placebo

    Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks

    Drug: Placebo

Interventions

  • Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI

  • DrugPlacebo

    Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 169 was defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 168 (i.e. at Week 24). Baseline FEV1 is defined as the mean of the two assessments made pre-dose at Visit 2 (Day 1). Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Modified intent-to-treat (mITT) Population comprised of all participants randomized to treatment who received at least one dose of the study medication in the treatment period.

    Time frame: Baseline (Day 1) and Day 169

Secondary outcomes

  1. Transition Dyspnea Index (TDI) Focal Score at Week 24 (Day 168)

    The Baseline Dyspnea Index (BDI) is used to measure the severity of dyspnea in participants at Baseline . The TDI measures changes in dyspnea severity from Baseline, as established by the BDI. TDI is formed of 3 individual scales that assess change in functional impairment, change in magnitude of task and change in magnitude of effort. The instrument is scored on a 7-point scale from -3 (major deterioration) to +3 (major improvement) for each category. Total scores (3 categories) range from -9 to +9 with lower scores indicating more deterioration in the severity of dyspnoea. A change of \>=1 units is considered to be the minimum clinically important difference (MCID) for the TDI.

    Time frame: Week 24 (Day 168)

  2. Change From Baseline in Weighted Mean FEV1 Over 0 to 6 Hours Post-dose on Day 1

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Weighted mean FEV1 was calculated over the nominal 0 to 6 hour post dose period. Values from post-dose assessments which were actually before the time of dosing were excluded from the calculation. The 0 hour value is the average value obtained 30 minutes and 5 minutes pre-dose, and both the 0 hour and 6 hour values must be present for a 0- to 6 hour weighted mean to be calculated. The 0 -to 6 hour weighted mean was derived by calculating the area under the FEV1 curve over the nominal time points of 0 hour, 15 and 30 minutes, 1, 3 and 6 hours, using the trapezoidal rule, and then dividing by the actual time between dosing and the 6 hour assessment. Baseline value for FEV1 was calculated from the values measured 30 minutes and 5 minutes pre-dose on Day 1. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.

    Time frame: Baseline (pre-dose on Day 1) and Day 1 (0 to 6 hours)

  3. Number of Participants With Adverse Events (AE) and Serious AE (SAE)

    AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or is associated with liver injury and impaired liver function.

    Time frame: Up to Day 178

  4. Change From Baseline in Vital Sign Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Vital signs (SBP and DBP) were obtained after participants had rested for approximately 5 minutes and before performing electrocardiogram (ECG) and spirometry testing. A single set of values was obtained. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Anytime post-Baseline values have been presented for SBP and DBP respectively.

    Time frame: Baseline (Day 1) to Day 169 (Visit 9)

  5. Change From Baseline in Vital Sign Parameter: Pulse Rate

    Vital sign pulse rate was obtained after participants had rested for approximately 5 minutes and before performing electrocardiogram (ECG) and spirometry testing. A single set of values was obtained. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Anytime post-Baseline values have been presented for pulse rate.

    Time frame: Baseline (Day 1) to Day 169 (Visit 9)

  6. Number of Participants With Electrocardiogram (ECG) Abnormalities Any Time Post Baseline

    A 12-lead ECG measurement was obtained after measurement of vital signs and before spirometry testing. Participants should be placed in the supine position for the ECG measurements. Any ECG abnormality recorded by a participant after the start of study treatment was included in the any-time post-Baseline record of all ECG abnormalities. Partcipants with abnormal ECG interpretation have been presented.

    Time frame: Up to Day 169 (Visit 9)

  7. Number of Participants With Hematology Data Outside the Normal Range at Any Time Post-Baseline

    Hematology parameters included basophils (normal range 0 to 0.2 giga cells/Liter), eosinophils (0.05 to 0.55 giga cells/Liter), hematocrit (0.36 to 0.49 percentage of red blood cells in blood), hemoglobin (118 to 168 gram/Liter), lymphocytes (0.85 to 4.1 giga cells/Liter), monocytes (0.2 to 1.1 giga cells/Liter), platelet count (PC)(130 to 400 giga cells/Liter), neutrophils (1.8 to 8 giga cells/Liter), total neutrophils (TN) (1.8 to 8 giga cells/Liter), white blood cell \[WBC\] count (3.8 to 10.8 giga cells/Liter). Only categories with non-zero (high and low) values at any time post Baseline have been presented.

    Time frame: Up to Day 168 (Visit 8)

  8. Number of Participants With Clinical Chemistry Data Outside the Normal Range at Any Time Post-Baseline

    Clinical chemistry parameters assessed included albumin (normal range 32 to 50 grams/Liter \[G/L\]), alkaline phosphatase (20 to 125 international units/Liter \[IU/L\]), alanine aminotransferase \[ALT\] (0 to 48 IU/L), aspartate aminotransferase \[AST\] (0 to 55 IU/L), direct bilirubin (0 to 6 micromoles/liter \[umol/l\]), indirect bilirubin (0 to 22 umol/l), total bilirubin (0 to 22 umol/l), calcium (2.12 to 2.56 milimoles/liter \[mmol/l\]), chloride (95 to 108 mmol/l), carbon dioxide \[CO2\] content/bicarbonate (20 to 32 mmol/l), creatinine (67.2 to 129.1 umol/l), creatinine phosphokinase \[CPK\] (0 to 235 IU/L), gamma glutamyl transferase \[GGT\] (0 to75 IU/L), glucose (3.9 to 6.9 mmol/l), phosphorus (0.7 to 1.4 mmol/l), potassium (3.5 to 5.3 mmol/l), protein total (58 to 81 G/L), sodium (135 to 146 mmol/l), urea nitrogen (2.5 to 10.5 mmol/l), uric acid (240 to 510 umol/l). Only categories with non-zero (high and low) values at any time post Baseline have been presented.

    Time frame: Up to Day 168 (Visit 8)

  9. Number of Participants With Abnormal Urinalysis Parameters by Dipstick Method

    Urinalysis parameters assessed were urine ketones, urine bilirubin, urine glucose, urine leukocyte esterase test for detecting WBC and urine protein. In this dipstick test, the level of bilirubin, glucose, leukocyte esterase and protein in urine samples was recorded as negative, trace, 1+, 2+, and 3+ (the plus sign increases with a higher level of bilirubin, glucose, leukocyte esterase, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to Day 168 (Visit 8). Only categories with significant values have been presented. Only those participants with data available at the indicated time point were analyzed.

    Time frame: Up to Day 168 (Visit 8)

  10. Mean Urine Potential of Hydrogen (pH)

    Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 to 6.0). Urine samples were collected for the measurement of urine pH up to Day 168 (Visit 8). Only categories with significant values have been presented. Only those participants with data available at the indicated time point were analyzed.

    Time frame: Day 168 (Visit 8)

  11. Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Days 28, 84 and 168

    The SGRQ is designed to measure health-related quality of life (HRQoL) in participants with diseases of airway obstruction with the use of 76 items grouped into three domains: symptoms, activity and impact. The questions are designed to be self-completed by the participant based on recall of the past 4 weeks. Domain score =sum of the weighted scores for the non-missing items within each domain/maximum possible score for those non-missing items x 100. The SGRQ total score= sum of the weighted scores from all 76 items /maximum possible score for the SGRQ x100. Scores range from 0, representing the best possible health status, to 100, representing the worst possible health status. A decrease in score indicates an improvement in HRQoL whereas increase indicates deterioration in HRQoL. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.

    Time frame: Baseline (Day 1) and Day 28, Day 84 and Day 168

  12. Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) Score at Days 28, 84 and 168

    The CAT is an 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. The CAT asks participant to score each item according to their current experience; there is no specific recall period. Items are scored on a 6-point response scale, with a score of 0 representing the participants are not experiencing the symptom/impact at all and a score of 5 representing a maximal symptom or impact. All items have equal weighting and so the total score is simply the sum of all scores and can range from 0 to a maximum of 40, with higher scores indicating a worse health state while a decrease in score indicates an improvement in health status. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.

    Time frame: Baseline (Day 1) and Days 28, 84 and 168

  13. Number of Participants With Healthcare Resource Utilization Status

    The total number of participants with visits for each type of healthcare contact ( office/practice visits, urgent care/outpatient clinic visits, emergency room visits and the intensive care visit and general wards visit have been presented.

    Time frame: Up to Day 169 (Visit 9)

  14. Number of Days Requiring Admission to Intensive Care Unit and General Ward

    The total number of days requiring admission to intensive care unit and general ward have been presented.

    Time frame: Up to Day 169 (Visit 9)

07

Results

Posted Jun 28, 2019

Participant flow

The study was conducted from 09 May 2016 to 08 November 2017 at 26 centers (21 centers in China and 5 centers in the Republic of Korea). A total of 306 participants were included in the Modified Intent-To-Treat (MITT) Population which comprised of all participants randomized to treatment who received at least one dose of study medication.

Participant flow — Overall Study
MilestonePlaceboUMEC 62.5 mcg
Started101205
Completed80177
Not completed2128
Withdrew: Lack of efficacy1115
Withdrew: Withdrawal by subject56
Withdrew: Adverse event45
Withdrew: Protocol violation11
Withdrew: Protocol defined stopping criteria01

Outcome measures

PrimaryChange From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 169 was defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 168 (i.e. at Week 24). Baseline FEV1 is defined as the mean of the two assessments made pre-dose at Visit 2 (Day 1). Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Modified intent-to-treat (mITT) Population comprised of all participants randomized to treatment who received at least one dose of the study medication in the treatment period.

Time frame:
Baseline (Day 1) and Day 169
Reported as:
Least squares mean · Liters
Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169
LitersPlaceboUMEC 62.5 mcg
Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169-0.022 ± 0.01710.131 ± 0.0117
Statistical analysis
  • Placebo vs UMEC 62.5 mcg · Mixed Models Repeated Measures (MMRM) · p = <0.001 (Analysis was performed using a MMRM model with covariates of treatment, Baseline, smoking status, country, Day, Day by Baseline and Day by treatment interactions.) · Least square mean difference: 0.154 · 95% CI 0.113 to 0.194
SecondaryTransition Dyspnea Index (TDI) Focal Score at Week 24 (Day 168)

The Baseline Dyspnea Index (BDI) is used to measure the severity of dyspnea in participants at Baseline . The TDI measures changes in dyspnea severity from Baseline, as established by the BDI. TDI is formed of 3 individual scales that assess change in functional impairment, change in magnitude of task and change in magnitude of effort. The instrument is scored on a 7-point scale from -3 (major deterioration) to +3 (major improvement) for each category. Total scores (3 categories) range from -9 to +9 with lower scores indicating more deterioration in the severity of dyspnoea. A change of \>=1 units is considered to be the minimum clinically important difference (MCID) for the TDI.

Time frame:
Week 24 (Day 168)
Reported as:
Least squares mean · Scores on a scale
Transition Dyspnea Index (TDI) Focal Score at Week 24 (Day 168)
Scores on a scalePlaceboUMEC 62.5 mcg
Transition Dyspnea Index (TDI) Focal Score at Week 24 (Day 168)1.6 ± 0.262.5 ± 0.17
Statistical analysis
  • Placebo vs UMEC 62.5 mcg · MMRM · p = 0.004 (Analysis performed using a MMRM model with covariates of treatment, BDI focal score, smoking status, country, Day, Day by BDI focal score and Day by treatment interactions.) · Least square mean difference: 0.9 · 95% CI 0.3 to 1.5
SecondaryChange From Baseline in Weighted Mean FEV1 Over 0 to 6 Hours Post-dose on Day 1

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Weighted mean FEV1 was calculated over the nominal 0 to 6 hour post dose period. Values from post-dose assessments which were actually before the time of dosing were excluded from the calculation. The 0 hour value is the average value obtained 30 minutes and 5 minutes pre-dose, and both the 0 hour and 6 hour values must be present for a 0- to 6 hour weighted mean to be calculated. The 0 -to 6 hour weighted mean was derived by calculating the area under the FEV1 curve over the nominal time points of 0 hour, 15 and 30 minutes, 1, 3 and 6 hours, using the trapezoidal rule, and then dividing by the actual time between dosing and the 6 hour assessment. Baseline value for FEV1 was calculated from the values measured 30 minutes and 5 minutes pre-dose on Day 1. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.

Time frame:
Baseline (pre-dose on Day 1) and Day 1 (0 to 6 hours)
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted Mean FEV1 Over 0 to 6 Hours Post-dose on Day 1
LitersPlaceboUMEC 62.5 mcg
Change From Baseline in Weighted Mean FEV1 Over 0 to 6 Hours Post-dose on Day 10.011 ± 0.00910.136 ± 0.0064
Statistical analysis
  • Placebo vs UMEC 62.5 mcg · ANCOVA · p = <0.001 (Analysis performed using an analysis of covariance (ANCOVA) model with covariates of treatment, baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status and country.) · Least square mean difference: 0.125 · 95% CI 0.103 to 0.147
SecondaryNumber of Participants With Adverse Events (AE) and Serious AE (SAE)

AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or is associated with liver injury and impaired liver function.

Time frame:
Up to Day 178
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) and Serious AE (SAE)
ParticipantsPlaceboUMEC 62.5 mcg
AE56122
SAE917
SecondaryChange From Baseline in Vital Sign Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Vital signs (SBP and DBP) were obtained after participants had rested for approximately 5 minutes and before performing electrocardiogram (ECG) and spirometry testing. A single set of values was obtained. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Anytime post-Baseline values have been presented for SBP and DBP respectively.

Time frame:
Baseline (Day 1) to Day 169 (Visit 9)
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Vital Sign Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryPlaceboUMEC 62.5 mcg
SBP, Anytime post-Baseline11.1 ± 11.2511.4 ± 10.64
DBP, Anytime post-Baseline-10.2 ± 7.55-10.8 ± 8.03
SecondaryChange From Baseline in Vital Sign Parameter: Pulse Rate

Vital sign pulse rate was obtained after participants had rested for approximately 5 minutes and before performing electrocardiogram (ECG) and spirometry testing. A single set of values was obtained. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value. Anytime post-Baseline values have been presented for pulse rate.

Time frame:
Baseline (Day 1) to Day 169 (Visit 9)
Reported as:
Mean · Beats/minute
Change From Baseline in Vital Sign Parameter: Pulse Rate
Beats/minutePlaceboUMEC 62.5 mcg
Change From Baseline in Vital Sign Parameter: Pulse Rate10.7 ± 10.948.2 ± 9.47
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities Any Time Post Baseline

A 12-lead ECG measurement was obtained after measurement of vital signs and before spirometry testing. Participants should be placed in the supine position for the ECG measurements. Any ECG abnormality recorded by a participant after the start of study treatment was included in the any-time post-Baseline record of all ECG abnormalities. Partcipants with abnormal ECG interpretation have been presented.

Time frame:
Up to Day 169 (Visit 9)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities Any Time Post Baseline
ParticipantsPlaceboUMEC 62.5 mcg
Number of Participants With Electrocardiogram (ECG) Abnormalities Any Time Post Baseline51105
SecondaryNumber of Participants With Hematology Data Outside the Normal Range at Any Time Post-Baseline

Hematology parameters included basophils (normal range 0 to 0.2 giga cells/Liter), eosinophils (0.05 to 0.55 giga cells/Liter), hematocrit (0.36 to 0.49 percentage of red blood cells in blood), hemoglobin (118 to 168 gram/Liter), lymphocytes (0.85 to 4.1 giga cells/Liter), monocytes (0.2 to 1.1 giga cells/Liter), platelet count (PC)(130 to 400 giga cells/Liter), neutrophils (1.8 to 8 giga cells/Liter), total neutrophils (TN) (1.8 to 8 giga cells/Liter), white blood cell \[WBC\] count (3.8 to 10.8 giga cells/Liter). Only categories with non-zero (high and low) values at any time post Baseline have been presented.

Time frame:
Up to Day 168 (Visit 8)
Reported as:
Count of participants · Participants
Number of Participants With Hematology Data Outside the Normal Range at Any Time Post-Baseline
ParticipantsPlaceboUMEC 62.5 mcg
Eosinophils, Any time post Baseline, High,n=96,196811
Eosinophils, Any time post Baseline, Low,n=96,1961937
Hematocrit, Any time post Baseline, High,n=96,1961435
Hematocrit, Any time post Baseline, Low,n=96,196321
Hemoglobin, Any time post Baseline, High,n=96,19625
Hemoglobin, Any time post Baseline, Low,n=96,196728
Lymphocytes, Any time post Baseline, High,n=96,19613
Lymphocytes, Any time post Baseline, Low,n=96,196310
Monocytes, Any time post Baseline, High,n=96,19601
Monocytes, Any time post Baseline, Low,n=96,1961428
PC, Any time post Baseline, High, n=96,19510
PC, Any time post Baseline, Low, n=96,195715
Neutrophils, Any time post Baseline, High,n=96,196812
Neutrophils,Any time post Baseline, Low,n=96,19602
TN, Any time post Baseline, High, n=96,196812
TN, Any time post Baseline, Low, n=96,19602
WBC count, Any time post Baseline, High,n=96,196712
WBC count, Any time post Baseline, Low,n=96,19601
SecondaryNumber of Participants With Clinical Chemistry Data Outside the Normal Range at Any Time Post-Baseline

Clinical chemistry parameters assessed included albumin (normal range 32 to 50 grams/Liter \[G/L\]), alkaline phosphatase (20 to 125 international units/Liter \[IU/L\]), alanine aminotransferase \[ALT\] (0 to 48 IU/L), aspartate aminotransferase \[AST\] (0 to 55 IU/L), direct bilirubin (0 to 6 micromoles/liter \[umol/l\]), indirect bilirubin (0 to 22 umol/l), total bilirubin (0 to 22 umol/l), calcium (2.12 to 2.56 milimoles/liter \[mmol/l\]), chloride (95 to 108 mmol/l), carbon dioxide \[CO2\] content/bicarbonate (20 to 32 mmol/l), creatinine (67.2 to 129.1 umol/l), creatinine phosphokinase \[CPK\] (0 to 235 IU/L), gamma glutamyl transferase \[GGT\] (0 to75 IU/L), glucose (3.9 to 6.9 mmol/l), phosphorus (0.7 to 1.4 mmol/l), potassium (3.5 to 5.3 mmol/l), protein total (58 to 81 G/L), sodium (135 to 146 mmol/l), urea nitrogen (2.5 to 10.5 mmol/l), uric acid (240 to 510 umol/l). Only categories with non-zero (high and low) values at any time post Baseline have been presented.

Time frame:
Up to Day 168 (Visit 8)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Data Outside the Normal Range at Any Time Post-Baseline
ParticipantsPlaceboUMEC 62.5 mcg
ALT, Any time post Baseline, High55
Albumin, Any time post Baseline, High01
Albumin, Any time post Baseline, Low01
Alkaline Phosphatase, Any time post Baseline, High35
Alkaline Phosphatase, Any time post Baseline, Low01
AST, Any time post Baseline, High03
Calcium, Any time post Baseline, Low21
CO2 content,Any time post Baseline, Low626
Chloride, Any time post Baseline, High08
Chloride, Any time post Baseline, Low22
Creatine Kinase, Any time post Baseline, High44
Creatinine, Any time post Baseline, High01
Creatinine, Any time post Baseline, Low2051
Direct Bilirubin, Any time post Baseline, High14
GGT, Any time post Baseline, High1012
Glucose, Any time post Baseline, High2346
Glucose, Any time post Baseline, Low21
Indirect Bilirubin, Any time post Baseline, High25
Phosphorus, Any time post Baseline, High98
Phosphorus, Any time post Baseline, Low35
Potassium, Any time post Baseline, High11
Potassium, Any time post Baseline, Low44
Sodium, Any time post Baseline, High11
Sodium, Any time post Baseline, Low14
Total Bilirubin, Any time post Baseline, High48
Total Protein, Any time post Baseline, High12
Total Protein, Any time post Baseline, Low01
Urea nitrogen, Any time post Baseline, High55
Urea nitrogen, Any time post Baseline, Low21
Uric acid, Any time post Baseline, High613
Uric acid, Any time post Baseline, Low1310
SecondaryNumber of Participants With Abnormal Urinalysis Parameters by Dipstick Method

Urinalysis parameters assessed were urine ketones, urine bilirubin, urine glucose, urine leukocyte esterase test for detecting WBC and urine protein. In this dipstick test, the level of bilirubin, glucose, leukocyte esterase and protein in urine samples was recorded as negative, trace, 1+, 2+, and 3+ (the plus sign increases with a higher level of bilirubin, glucose, leukocyte esterase, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to Day 168 (Visit 8). Only categories with significant values have been presented. Only those participants with data available at the indicated time point were analyzed.

Time frame:
Up to Day 168 (Visit 8)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Parameters by Dipstick Method
ParticipantsPlaceboUMEC 62.5 mcg
Urine Bilirubin, Day 168, 1+22
Urine Bilirubin, Day 168, 2+10
Urine Glucose, Day 168, 1+36
Urine Glucose, Day 168, 2+21
Urine Glucose, Day 168, 3+22
Urine Glucose, Day 168, Trace22
Urine leukocyte esterase, Day 168, 1+11
Urine leukocyte esterase, Day 168, 2+02
Urine leukocyte esterase, Day 168, Trace42
Urine protein, Day 168, 1+21
Urine protein, Day 168, 2+10
Urine protein, Day 168, Trace106
SecondaryMean Urine Potential of Hydrogen (pH)

Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 to 6.0). Urine samples were collected for the measurement of urine pH up to Day 168 (Visit 8). Only categories with significant values have been presented. Only those participants with data available at the indicated time point were analyzed.

Time frame:
Day 168 (Visit 8)
Reported as:
Mean · pH
Mean Urine Potential of Hydrogen (pH)
pHPlaceboUMEC 62.5 mcg
Mean Urine Potential of Hydrogen (pH)6.16 ± 0.5206.25 ± 0.632
SecondaryChange From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Days 28, 84 and 168

The SGRQ is designed to measure health-related quality of life (HRQoL) in participants with diseases of airway obstruction with the use of 76 items grouped into three domains: symptoms, activity and impact. The questions are designed to be self-completed by the participant based on recall of the past 4 weeks. Domain score =sum of the weighted scores for the non-missing items within each domain/maximum possible score for those non-missing items x 100. The SGRQ total score= sum of the weighted scores from all 76 items /maximum possible score for the SGRQ x100. Scores range from 0, representing the best possible health status, to 100, representing the worst possible health status. A decrease in score indicates an improvement in HRQoL whereas increase indicates deterioration in HRQoL. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.

Time frame:
Baseline (Day 1) and Day 28, Day 84 and Day 168
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Days 28, 84 and 168
Scores on a scalePlaceboUMEC 62.5 mcg
Day 28, n=91,188-1.45 ± 1.174-5.84 ± 0.813
Day 84, n= 84,183-2.46 ± 1.268-7.05 ± 0.860
Day 168, n=78,176-4.31 ± 1.316-7.34 ± 0.882
Statistical analysis
  • Placebo vs UMEC 62.5 mcg · MMRM · p = 0.002 (Analysis performed using a repeated measures model with covariates of treatment, Baseline (score prior to dosing on Day 1), smoking status, country, Day, Day by Baseline and Day by treatment interactions.) · Least sqaure mean difference: -4.39 · 95% CI -7.21 to -1.58
  • Placebo vs UMEC 62.5 mcg · MMRM · p = 0.003 (Analysis performed using a repeated measures model with covariates of treatment, Baseline (score prior to dosing on Day 1), smoking status, country, Day, Day by Baseline and Day by treatment interactions.) · Least square mean difference: -4.59 · 95% CI -7.61 to -1.57
  • Placebo vs UMEC 62.5 mcg · MMRM · p = 0.058 (Analysis performed using a repeated measures model with covariates of treatment, Baseline (score prior to dosing on Day 1), smoking status, country, Day, Day by Baseline and Day by treatment interactions.) · Least sqaure mean difference: -3.03 · 95% CI -6.15 to 0.10
SecondaryChange From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) Score at Days 28, 84 and 168

The CAT is an 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. The CAT asks participant to score each item according to their current experience; there is no specific recall period. Items are scored on a 6-point response scale, with a score of 0 representing the participants are not experiencing the symptom/impact at all and a score of 5 representing a maximal symptom or impact. All items have equal weighting and so the total score is simply the sum of all scores and can range from 0 to a maximum of 40, with higher scores indicating a worse health state while a decrease in score indicates an improvement in health status. Baseline was the most recent recorded value before dosing on Day 1 at schedule visit. Change from Baseline was calculated by subtracting the value on-treatment from the Baseline value.

Time frame:
Baseline (Day 1) and Days 28, 84 and 168
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) Score at Days 28, 84 and 168
Scores on a scalePlaceboUMEC 62.5 mcg
Day 28, n=94,199-0.26 ± 0.551-1.75 ± 0.378
Day 84, n=87,189-0.08 ± 0.594-2.18 ± 0.403
Day 168, n=80,179-1.32 ± 0.648-2.00 ± 0.434
Statistical analysis
  • Placebo vs UMEC 62.5 mcg · MMRM · p = 0.027 (Analysis performed using a repeated measures model with covariates of treatment, Baseline (score prior to dosing on Day 1), smoking status, country, Day, Day by Baseline and Day by treatment interactions.) · Least sqaure mean difference: -1.49 · 95% CI -2.81 to -0.17
  • Placebo vs UMEC 62.5 mcg · MMRM · p = 0.004 (Analysis performed using a repeated measures model with covariates of treatment, Baseline (score prior to dosing on Day 1), smoking status, country, Day, Day by Baseline and Day by treatment interactions.) · Least square mean difference: -2.10 · 95% CI -3.51 to -0.68
  • Placebo vs UMEC 62.5 mcg · MMRM · p = 0.386 (Analysis performed using a repeated measures model with covariates of treatment, Baseline (score prior to dosing on Day 1), smoking status, country, Day, Day by Baseline and Day by treatment interactions.) · Least square mean difference: -0.68 · 95% CI -2.22 to 0.86
SecondaryNumber of Participants With Healthcare Resource Utilization Status

The total number of participants with visits for each type of healthcare contact ( office/practice visits, urgent care/outpatient clinic visits, emergency room visits and the intensive care visit and general wards visit have been presented.

Time frame:
Up to Day 169 (Visit 9)
Reported as:
Count of participants · Participants
Number of Participants With Healthcare Resource Utilization Status
ParticipantsPlaceboUMEC 62.5 mcg
Office/Practice Visits412
Urgent Care/Outpatient Clinic Visits1110
Emergency Room Visits11
SecondaryNumber of Days Requiring Admission to Intensive Care Unit and General Ward

The total number of days requiring admission to intensive care unit and general ward have been presented.

Time frame:
Up to Day 169 (Visit 9)
Reported as:
Number · Days
Number of Days Requiring Admission to Intensive Care Unit and General Ward
DaysPlaceboUMEC 62.5 mcg
Days in Intensive Care Unit00
Days in General Ward3520

Adverse events

Collected over AE and nSAE were collected from Day 1 to Day 178. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/101 (0%)9/101 (8.9%)32/101 (31.7%)
UMEC 62.5 mcg1/205 (0.5%)17/205 (8.3%)52/205 (25.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlaceboUMEC 62.5 mcg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders5/1015/205
PneumoniaInfections and infestations1/1012/205
Lung infectionInfections and infestations1/1010/205
ConcussionInjury, poisoning and procedural complications1/1010/205
Type 2 diabetes mellitusMetabolism and nutrition disorders1/1011/205
CataractEye disorders1/1010/205
Pulmonary tuberculosisInfections and infestations0/1011/205
Chest painGeneral disorders0/1011/205
Sudden deathGeneral disorders0/1011/205
Cervical vertebral fractureInjury, poisoning and procedural complications0/1011/205
Most frequent other events
Most frequent other events
EventPlaceboUMEC 62.5 mcg
Upper respiratory tract infectionInfections and infestations13/10125/205
NasopharyngitisInfections and infestations11/10119/205
Urinary tract infectionInfections and infestations3/1012/205
Blood glucose increasedInvestigations3/1012/205
Benign prostatic hyperplasiaReproductive system and breast disorders3/1010/205
DizzinessNervous system disorders2/1016/205

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboUMEC 62.5 mcgTotal
Mean65.7 ± 7.0565.5 ± 6.8965.6 ± 6.93
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUMEC 62.5 mcgTotal
Female41216
Male97193290
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUMEC 62.5 mcgTotal
Asian - East Asian Heritage101205306
08

Study locations

26 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510630, China
  • GSK Investigational Site
    Zhanjiang, Guangdong 524001, China
  • GSK Investigational Site
    Haikou, Hainan 570311, China
  • GSK Investigational Site
    Huhhot, Inner Mongolia 010017, China
  • GSK Investigational Site
    Wuxi, Jiangsu 214023, China
  • GSK Investigational Site
    Nanchang, Jiangxi 330006, China
  • GSK Investigational Site
    Changchun, Jilin 130041, China
  • GSK Investigational Site
    Shenyang, Liaoning 110004, China
  • GSK Investigational Site
    Shenyang, Liaoning 110015, China
  • GSK Investigational Site
    Yinchuan, Ningxia 750004, China
  • GSK Investigational Site
    Jinan, Shandong 250013, China
  • GSK Investigational Site
    Qingdao, Shandong 266071, China
  • GSK Investigational Site
    Taiyuan, Shanxi, China
  • GSK Investigational Site
    Hangzhou, Zhejiang, China
  • GSK Investigational Site
    Beijing, 100034, China
  • GSK Investigational Site
    Changsha, 410013, China
  • GSK Investigational Site
    Chongqing, 400038, China
  • GSK Investigational Site
    Chongqing, China
  • GSK Investigational Site
    Guangzhou, 510120, China
  • GSK Investigational Site
    Nanchang, 330006, China
  • GSK Investigational Site
    Shanghai, 200433, China
  • GSK Investigational Site
    Gyeonggi-do, 410-719, Korea, Republic of
  • GSK Investigational Site
    Seoul, 130-709, Korea, Republic of
  • GSK Investigational Site
    Seoul, 130-872, Korea, Republic of
  • GSK Investigational Site
    Seoul, 380-704, Korea, Republic of
  • GSK Investigational Site
    Suwon, 442-723, Korea, Republic of
09

References and documents

Publications

  • Zhong N, Zheng J, Lee SH, Lipson DA, Du X, Wu S. Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study. Int J Chron Obstruct Pulmon Dis. 2020 Apr 17;15:809-819. doi: 10.2147/COPD.S215011. eCollection 2020. PubMed 32368027 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Nov 2017, 17 months.

Results were first posted in Jun 2019, 1 year 7 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 17 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2014
First posted
Jul 9, 2014
StartActual
May 9, 2016
Primary completionActual
Nov 8, 2017
CompletionActual
Nov 8, 2017
Results first posted
Jun 28, 2019
Last update
Jun 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02184611
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 9, 2014
Start date
May 9, 2016
Primary completion
Nov 8, 2017
Completion
Nov 8, 2017
Results posted
Jun 28, 2019
Last update
Jun 29, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Umeclidinium bromide

Start the discussion